Tradjenta

Type: Product
Name: Tradjenta
First reported Apr 16 2014 - Updated Apr 16 2014 - 1 reports

New report finds Bydureon safest of new class of diabetes drugs

Analysis of FDA adverse event data tries to pull together risks of three new classes of drugsShareToolsBydureon--Courtesy of AstraZenecaWith big money to be made, drugmakers have responded to the global rise in Type 2 diabetes with a host of new classes ... [Published FiercePharma - Apr 16 2014]
First reported Apr 16 2014 - Updated Apr 16 2014 - 1 reports

AdverseEvents' Special Report: Examining the Comparative Safety of Type 2 Diabetes Drugs

Type 2 Diabetes Drugs Safety Review: Byetta Has Best Safety Profile, Nesina Shows Worst Safety ProfileType 2 Diabetes affects approximately 230 million people worldwide and incidence is growing at an alarming rate. To address this epidemic, new drugs ... [Published FiercePharma - Apr 16 2014]
First reported Apr 15 2014 - Updated Apr 16 2014 - 2 reports

US FDA accepts NDA filing of empagliflozin and linagliptin combo drug to treat adults with type 2 diabetes

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company announced that the US Food and Drug Administration (FDA) accepted the filing of the New Drug Application (NDA) for the investigational combination tablet of empagliflozin and linagliptin ... [Published PharmaBiz - Apr 16 2014]
First reported Apr 15 2014 - Updated Apr 15 2014 - 3 reports

Eli Lilly/ Boehringer Drug Under FDA Review - Analyst Blog

Eli Lilly and Company (NYSE: LLY) and partner Boehringer Ingelheim Pharmaceuticals, Inc. announced that the new drug application (NDA) for their empagliflozin−Tradjenta (linagliptin) combination has been accepted for review by the U.S. Food and Drug Administration ... [Published Benzinga.com - Apr 15 2014]
First reported Apr 15 2014 - Updated Apr 15 2014 - 1 reports

BI rethinks hepatitis business, posts 2013 results

Share this article:BI expects to "face challenges" in 2014Family-owned Boehringer Ingelheim is bracing for rough 2014. The drugmaker indicated in its 2013 annual report that “we can expect to face challenges,” and that it is not expecting BI, let alone ... [Published Medical Marketing And Media - Apr 15 2014]
First reported Apr 14 2014 - Updated Apr 15 2014 - 2 reports

FDA Accepts BI, Lilly NDA for Type 2 Diabetes Combo Tablet

Boehringer Ingelheim Pharmaceuticals Inc. and Eli Lilly and Co. announced the U.S. Food and Drug Administration (FDA) accepted the filing of the New Drug Application (NDA) for the investigational combination tablet of empagliflozin and linagliptin for ... [Published Drug Discovery and Development - Apr 14 2014]
First reported Apr 06 2014 - Updated Apr 06 2014 - 1 reports

Patient Handout: 7 Tips to Drop Excess Pounds with Diabetes

Losing weight when you have diabetes can be a good news-bad news thing. The good news is that dropping even a few pounds can help reduce your need for diabetes medications.When adults with diabetes lose just seven percent of their body weight (only 14 ... [Published Diabetes in Control - Apr 06 2014]
Entities: Diabetes, Insulin, Metformin
First reported Mar 28 2014 - Updated Mar 28 2014 - 1 reports

DPP-4 Inhibitors -- An Update on Alogliptin

Edward C. Chao, MDDisclosuresAccessMedicine from McGraw-HillOverview and Introduction OverviewAlogliptin (NESINA), a dipeptidyl peptidase IV (DPP-4) inhibitor, was approved by the FDA on January 25, 2013 to improve blood sugar control in adults with ... [Published Diabetes Care - Mar 28 2014]
Entities: DPP-4, Alogliptin, GLP-1
First reported Mar 19 2014 - Updated Mar 19 2014 - 1 reports

FirstWord Lists – Diabetes launches to continue unabated: what is in the late-stage pipeline?

The diabetes market will be shaped by the entrance of a succession of new products over the next few years, many of which will compete with each other.Driven by ageing populations and the increasing incidence of diabetes, the market is expected to enjoy ... [Published FirstWord Pharma - Mar 19 2014]
First reported Mar 17 2014 - Updated Mar 18 2014 - 2 reports

Toothpaste and canker sores

Q: I was troubled with recurrent canker sores for a while. The only thing that had changed was my toothpaste. I wanted whiter teeth, so I was using whitening toothpastes.I got canker sores when there was sodium lauryl sulfate (SLS) in the toothpaste. ... [Published Charlotte Observer - Mar 18 2014]
First reported Mar 07 2014 - Updated Mar 07 2014 - 1 reports

What Do Pharma's "High Performers" Have in Common?

A new study of high-performing pharma companies reveals science-based innovation strategies and patient-outcome-based commercial models are now the key drivers of growth. Anne O’Riordan reports.A select group of high performing pharma companies are significantly ... [Published Pharmaceutical Executive - Mar 07 2014]
First reported Mar 03 2014 - Updated Mar 03 2014 - 1 reports

The New Metrics of Market Success

Pharma companies active in the US market recognize the declining importance of physicians compared to the increased cloutof payers, provider organizations and patients. Many have moved toward new commercial models and repositioned sales resourcesto achieve ... [Published Pharmaceutical Executive - Mar 03 2014]

Quotes

...said Christophe Arbet-Engels, vice president, metabolic-clinical development and medical affairs, Boehringer Ingelheim Pharmaceuticals, Inc. "Adults living with type 2 diabetes often take more than one therapy to manage their condition, and we hope the combination of these two products will help them improve control of their blood sugar."
...about these allegations and their legal options to seek compensation will not be interrupted by the holiday season,” said Resource4thePeople. "In response to numerous inquiries from consumers who have asked about whether our attorneys will be available over the holidays we are announcing that our 24-hour hotline will be staffed for those who may be seeking legal options about their eligibility to seek compensation." The multidistrict litigation in U S District Court for the SouthernSouthern District of California was approved** by a federal judiciary panel because...
...29, 2013, and the defendants must file their master consolidated answer no later than Dec. 31, 2013. "This order was issued after the latest status conference on Nov. 21, 2013, at which the judge was briefed on the progress of the case by attorneys for both sides,” said Resource4thePeople. “The filing of a master complaint will define the allegations in this litigation and the response will provide an answer to the charges from the defendants."
...process of pre-trial evidence gathering and other legal actions before bringing these cases to settlement or trials," said Resource4thePeople. "As this process continues we are assuring consumers who may have been affected by allegations involving Januvia, Janumet, Byetta and Victoza that our nationwide network of attorneys will continue to provide free consultations for those who wish to determine what their rights to seek compensation may be." The multidistrict litigation in U S District Court for the SouthernSouthern District of California was approved** by a federal judiciary panel because...

More Content

All (28) | News (28) | Reports (0) | Blogs (0) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
New report finds Bydureon safest of new class o... [Published FiercePharma - Apr 16 2014]
AdverseEvents' Special Report: Examining the Co... [Published FiercePharma - Apr 16 2014]
US FDA accepts NDA filing of empagliflozin and ... [Published PharmaBiz - Apr 16 2014]
Eli Lilly/ Boehringer Drug Under FDA Review - A... [Published Benzinga.com - Apr 15 2014]
Eli Lilly/ Boehringer Drug Under FDA Review - A... [Published Zacks.com - Apr 15 2014]
Eli Lilly/ Boehringer Drug Under FDA Review [Published Yahoo! Finance - Apr 15 2014]
BI rethinks hepatitis business, posts 2013 results [Published Medical Marketing And Media - Apr 15 2014]
Empagliflozin/Linagliptin Tablet Submitted for ... [Published P&T Community - Apr 15 2014]
FDA Accepts BI, Lilly NDA for Type 2 Diabetes C... [Published Drug Discovery and Development - Apr 14 2014]
NDA filing for empagliflozin and linagliptin co... [Published Pharma Letter - Apr 14 2014]
Lilly: FDA Accepts NDA For Combination Tablet O... [Published RTTNews.com - Apr 14 2014]
Patient Handout: 7 Tips to Drop Excess Pounds w... [Published Diabetes in Control - Apr 06 2014]
DPP-4 Inhibitors -- An Update on Alogliptin [Published Diabetes Care - Mar 28 2014]
FirstWord Lists – Diabetes launches to continue... [Published FirstWord Pharma - Mar 19 2014]
Toothpaste and canker sores [Published Charlotte Observer - Mar 18 2014]
Many options to naturally control your blood sugar [Published OnlineAthens - Mar 17 2014]
What Do Pharma's "High Performers" Have in Common? [Published Pharmaceutical Executive - Mar 07 2014]
The New Metrics of Market Success [Published Pharmaceutical Executive - Mar 03 2014]
Januvia Pancreatic Cancer Allegations Help: Res... [Published PRWeb - Feb 27 2014]
Januvia Pancreatic Cancer Allegations Alert: Re... [Published PRWeb - Jan 19 2014]
Byetta Pancreatic Cancer Allegations Attorneys:... [Published PRWeb - Dec 19 2013]
Byetta Pancreatic Cancer Allegation Attorneys: ... [Published PRWeb - Nov 27 2013]
Byetta Pancreatic Cancer Allegations Lawyers: R... [Published PRWeb - Nov 05 2013]
Latest Januvia Lawsuits Alleging Pancreatic Can... [Published PRWeb - Oct 14 2013]
Byetta Lawsuits Alleging Pancreatic Cancer Help... [Published PRWeb - Sep 13 2013]
Linagliptin shows HbA1c reduction in type 2 dia... [Published PharmaBiz - Aug 17 2013]
Eli Lilly's net earnings jumps by 31% in Q2 [Published PharmaBiz - Jul 25 2013]
New Byetta Pancreatic Cancer Allegation Lawsuit... [Published PRWeb - Jul 24 2013]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.